多西他赛联合重组人血管内皮抑素治疗非小细胞肺癌的临床效果

Clinical efficacy of docetaxel combined with recombinant human endo-statin in the treatment of non-small cell lung cancer

目的探讨多西他赛联合重组人血管内皮抑素治疗非小细胞肺癌（NSCLC）的临床效果。方法选择2010年1月~2013年3月收治的76例一线化疗初治后进展或不能耐受毒性反应的NSCLC患者,观察组38例给予多西他赛联合重组人血管内皮抑素治疗,对照组38例采用单药多西他赛治疗,比较两组的疾病进展时间（TTP）、客观缓解率（ORR）、临床受益率（CBR）及不良反应情况。结果观察组及对照组的ORR均为0,CBR分别为63.2%（24/38）和52.6%（20/38）（P=0.712）。观察组及对照组的TTP分别为（2.6±0.4）、（2.0±0.8）个月（P=0.083）。观察组及对照组初治后进展的TTP分别为（1.3±0.4）、（1.6±0.8）个月（P=0.907）;不能耐受毒性的TTP分别为（4.7±0.1）、（3.1±0.8）个月（P=0.092）。观察组及对照组经治疗后获疾病稳定患者的TTP分别为（6.2±0.4）、（3.2±0.8）个月,观察组较对照组长（P=0.038）。观察组及对照组的不良反应比较差异无统计学意义（P〉0.05）。结论对于初治后进展或不能耐受毒性反应的NSCLC患者,重组人血管内皮抑素在不增加毒副作用的情况下可延长多西他赛化疗获益患者的TTP。

Objective To analyze the efficacy of docetaxel combined with recombinant human endostatin in the treatment of non-small cell lung cancer（NSCLC）. Methods 76 patients with stage ⅢB/Ⅳof NSCLC experienced previous chemotherapy of one-regimen were screened for this study from January 2010 to March 2013.The docetaxel combined with recombinant human endostatin were used in observation group（n =38）,the only docetaxel was applied in control group（n=38）.The response time to progression（TTP）,objective response rate（ORR）,clinical benefit rate（CBR）and adverse effect were observed in two groups. Results ORR and CBR was 0 and 63.2%（24/38）in observation group respectively,ORR and CBR was 0 and 52.6%（20/38）in control group respectively.CBR of two groups was compared,with no statistical difference（P =0.712）.TTP in observation group and control group was（2.6 ±0.4）and（2.0 ±0.8）months respectively（P =0.083）.TTP after the initial treatment progress in observation group and control group was（1.3±0.4）and（1.6±0.8） months respectively（P=0.907）.TTP with can not tolerate the toxicity in observation group and control group was（4.7±0.1）and（3.1 ±0.8） months respectively（P =0.092）.TTP of the patients with SD after therapeutic cycle in observation group and control group was（6.2±0.4）and（3.2±0.8）months respectively,observation group was longer than that control group（P=0.038）.The adverse effect in two groups was compared,with no statistical difference（P〈0.05）. Conclusion Recombinant human endostatin may prolong TTP in patients with advanced NSCLC benefited from docetaxel treatment without increased toxicity.